News for Ikena Oncology, Inc. (IKNA)

Combined Company to Trade on Nasdaq Under Ticker ”œIMA” Ikena Announces 1-for-12 Reverse Stock Split of Ikena Common Stock BOSTON and SAN DIEGO, July 15,

Stockholders of Ikena Oncology (IKNA) approved a merger with Inmagene Biopharmaceuticals, forming ImageneBio, Inc. The new company will trade under the

Ikena Oncology (IKNA) has announced that two prominent advisory firms, Institutional Shareholder Services and Glass, Lewis & Co., have advised shareholders to s

BOSTON, July 11, 2025 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, 'Ikena,” the 'Company”) today announced that Institutional Shareholder Services Inc. ('ISS”) and Glass, Lewis & Co. ('Glass Lewis”) recommend that stockholders vote FOR the issuance of shares in connection with the previously disclosed proposed merger with Inmagene Biopharmaceuticals ('Inmagene”) at Ikena’s upcoming Annual Meeting of Stockholders on July 15, 2025.

Werner Cautreels, PhD, to retire as CEO, while continuing as a Board MemberIain D. Dukes, D Phil, Executive Board Chairman, to become Interim CEO NEWTOWN, Pa.,

**media[579911]**

65% oncology products revenue growth drove profitable operation and supported new ATTC platform HONG KONG and SHANGHAI and FLORHAM PARK, N.J., March 19, 2025

**media[570625]**

On February 7, 2025, Deep Track Capital, LP (Trades, Portfolio) executed a strategic acquisition of 2,515,513 shares in Ikena Oncology Inc. The transaction was

Transaction Overview On December 31, 2024, BIOTECHNOLOGY VALUE FUND L P (Trades, Portfolio) executed a significant transaction involving Ikena Oncology Inc (IKN

**media[510906]**

Ikena Oncology (IKNA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Ikena Oncology ( (IKNA) ) has provided an announcement. Ikena Oncology and Inmagene Biopharmaceuticals have announced a definitive merger agreement, under which the combined company will focus on developing IMG-007, a monoclonal antibody aimed at treating atopic dermatitis and other inflammatory conditions. The transaction involves a private placement raising approximately $175 million, including $75 million from new and existing investors, and is expected to close in mid-2025. Following the mer

Inmagene Biopharmaceuticals is a clinical stage company focused on developing IMG-007, a non-depleting anti-OX40 monoclonal antibody with an extended half-life

Ikena Oncology and Inmagene Biopharmaceuticals are merging to focus on developing a monoclonal antibody for atopic dermatitis treatment.

IKNA stock results show that Ikena Oncology beat analyst estimates for earnings per share the second quarter of 2024.

Strong financial position with $145 million in cash and investments at close of second quarter...

Wedbush has downgraded Ikena Oncology (IKNA) to neutral, citing Tuesday’s announcement that the company was discontinuing development of its lead asset, IK-930. Read more here.

Loading... Loading... Shares of Bank of Montreal BMO fell sharply during Wednesday's session after the company reported worse-than-expected second-quarter fina...